Sprache auswählen


Bain & Company, 2023

The biopharma industry, which has experienced remarkable productivity over the past 30 years, is expected to face challenges in the next decade, including slowing revenue growth and increasing costs.

To sustain productivity, companies can redefine category leadership, adapting to changes in clinical decision-making; embrace digital disruption by adopting a digital-first approach to operations; and explore consortia approaches to collaborate on the development, manufacturing, and commercialization of novel therapies, reducing costs and enhancing productivity. These strategies will be crucial for biopharma companies to adapt, grow, and maintain shareholder returns in the face of a changing landscape.

Read the whole article here